NEW YORK, Oct. 13, 2013 /PRNewswire/ --

Achillion Pharmaceuticals, Inc. Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the District of Connecticut, alleging that Achillion Pharmaceuticals, Inc. ("Achillion") issued false and misleading statements to investors between April 21, 2012 and September 27, 2013, inclusive (the "Class Period") by failing to disclose that sovaprevir in fact did not interact well with other drugs commonly administered to treat hepatitis and/or HIV.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@

jlclasslaw.com
.

ARIAD Pharmaceuticals, Inc. Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the District of Massachusetts, alleging that ARIAD Pharmaceuticals, Inc. (the "Company" or "ARIA") issued false and misleading statements to investors between December 12, 2011 and October 8, 2013, inclusive (the "Class Period"). Specifically, on October 9, 2013, the Company disclosed that the updated data from its PACE trial revealed that Iclusig was shown to cause a higher rate of blood clots and heart-related side effects than previously disclosed, that the U.S. Food and Drug Administration ("FDA") placed a hold on new patient enrollment for Iclusig testing, and that the Company advised patients currently receiving the drug to lower their dosage,

The firm is investigating legal claims against the officers and Board of Directors of the Company.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Brazil Fast Food Corp. Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Brazil Fast Food Corp. ("BOBS") to Figueiredo Bomeny, its CEO, and certain other shareholders (collectively, the "Investor Group") in an all-cash deal valued at approximately US$15.50 in cash per share or a total equity value of approximately US$32,556,045.

Lifshitz Law Firm's investigation is focused on whether the proposed deal provides adequate value to BOBS' shareholders.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Camco Financial Corporation Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Camco Financial Corporation ("CAFI") to Huntington Bancshares Incorporated in a cash and stock transaction valued at approximately $97 million including outstanding options and warrants.

Lifshitz Law Firm's investigation is focused on whether the proposed deal provides adequate value to CAFI shareholders.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Lifshitz Law Firm is a New York based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.jlclasslaw.com.

ATTORNEY ADVERTISING. © 2013 Lifshitz Law Firm. The law firm responsible for this advertisement is Lifshitz Law Firm, 18 East 41st Street, New York, New York 10017, (212) 213-6222. Prior results do not guarantee or predict a similar outcome with respect

to any future matter
.

Contact:Joshua M. Lifshitz, Esq.Lifshitz Law FirmPhone: 212-213-6222 Email: info@jlclasslaw.com

SOURCE Lifshitz Law Firm

RELATED LINKS http://www.jlclasslaw.com